Ameloblastoma Diagnosis From Serum Metabolic Profiling
Oral Diseases · 2025
DOI: 10.1111/odi.15308 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Peiyin Sun und 3 weiteren Autor:innen. Beteiligte Einrichtung: General Dentistry, Shanghai Children's Medical Center, School of Medicine, Jiaotong University, Shanghai, China. Hauptthemen laut MEDLINE: Ameloblastoma, Jaw Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 33 Literaturangaben. Gefördert von: 3456 Key Talents Funding Project of Nanjing Stomatological Hospital Medical School of Nanjing University, General Project of Nanjing Health Science and Technology Development Special Fund, Medical Research Projects of Health Commission of Jiangsu Province.
Abstract (Originalsprache)
Introduction
Ameloblastoma (ABM) is an aggressive, localized, infiltrating epithelial odontogenic neoplasm. The molecular pathogenesis of ABM is unknown, and studying its metabolic profile may allow the identification of biomarkers relevant to the diagnosis and prediction of pathology.
Methods
Metabolomic analysis of 41 serum samples from 21 ABM patients and 20 healthy controls (HCs) was performed using gas chromatography–mass spectrometry (GC–MS). Using LASSO regression and receiver operating characteristic analysis, biomarker metabolites were screened and validated, and a diagnostic model was established. Tissue samples from ABM patients were analyzed using BRAF V600E‐specific immunohistochemistry to investigate the impact of the BRAF V600E mutation on metabolic reprogramming in ABM.
Results
A total of 73 metabolites were identified in the samples. The ABM had a total of 32 dysregulated metabolites, of which 30 were downregulated. A diagnostic panel of 10 metabolites was then generated. The panel accurately identified ABM with 100% sensitivity, 100% specificity, and an AUC of 1.00. In addition, the presence of the BRAF‐V600E mutation in ABM is associated with increased serum glutamine levels.
Conclusion
This study identified distinct metabolic characteristics of ABM and established a diagnostic model. Our research also shows that BRAF‐V600E may contribute to metabolic alterations in ABM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Dentistry, Shanghai Children's Medical Center, School of Medicine, Jiaotong University, Shanghai, China.
- Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Institute of Stomatology, Nanjing University, Nanjing, Jiangsu, China.
- Department of Pediatric Dentistry, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Research Institute of Stomatology, Nanjing University, Nanjing, Jiangsu, China.
ORCID-Profile: Peiyin Sun, Shuai Wang
Förderung
- 3456 Key Talents Funding Project of Nanjing Stomatological Hospital Medical School of Nanjing University
- General Project of Nanjing Health Science and Technology Development Special Fund
- Medical Research Projects of Health Commission of Jiangsu Province
Zitieren
APA
Sun, P., Wang, S., Wang, Y., & Wei, Z. (2025). Ameloblastoma Diagnosis From Serum Metabolic Profiling. Oral Diseases. https://doi.org/10.1111/odi.15308
Vancouver
Sun P, Wang S, Wang Y, Wei Z. Ameloblastoma Diagnosis From Serum Metabolic Profiling. Oral Diseases. 2025. doi:10.1111/odi.15308
BibTeX
@article{Sun2025,
author = {Sun, Peiyin and Wang, Shuai and Wang, Yali and Wei, Zheng},
title = {Ameloblastoma Diagnosis From Serum Metabolic Profiling},
journal = {Oral Diseases},
year = {2025},
doi = {10.1111/odi.15308}
}
EUVIMED